Form 4 for INO INOVIO PHARMACEUTICALS, INC.
Accepted 2022-05-17 00:00:00 ET · period of report 2022-05-13 · accession 0001055726-22-000038 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-17 | 2022-05-13 | INO | BENITO SIMON X | Dir | M - OptEx | — | +18.0K | 75.3K | +31% | — |
| DM | 2022-05-17 | 2022-05-16 | INO | BENITO SIMON X | Dir | A - Grant | $0.00 | +47.0K | 28.0K | New | $0 |
| D | 2022-05-17 | 2022-05-13 | INO | BENITO SIMON X | Dir | M - OptEx | $0.00 | -18.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-13 | M | A | 18,000 | — | 75,305 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. |
| 2 | Derivative | Restricted Stock Unit | 2022-05-16 | A | A | 19,000 | $0.00 | 19,000 | D | — · — to — | 19,000 Common Stock | (F3) This grant was made pursuant to the issuer's non-employee director compensation policy. (F2) Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 16, 2023. |
| 3 | Derivative | Restricted Stock Unit | 2022-05-13 | M | D | 18,000 | $0.00 | 0 | D | — · — to — | 18,000 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 13, 2022. |
| 4 | Derivative | Common Stock Options | 2022-05-16 | A | A | 28,000 | $0.00 | 28,000 | D | $1.89 · — to 2032-05-16 | 28,000 Common Stock | (F3) This grant was made pursuant to the issuer's non-employee director compensation policy. (F4) Options to vest 100% on May 16, 2023. |